Replies to post #147988 on Anavex Life Sciences Corp (AVXL)

[TheBigTicket]

Awesome job JonJones

[nidan7500]

Jonjones325...and Bourbon...

Exceptional, above and beyond. Well done, thanks.

[BCCHoosier]

Don't get lazy on us now. I kid..I kid. Thanks so much for your efforts.

[XenaLives]

Why partner for half a loaf if six months to a year you can get the whole loaf?

-Biogen MTA – Long shot, too early. Next step is to do a model study. Missling said they have enough on their plate already.

[Investor2014]

LUND will not be conducting the trial. They are PHDs not MDs. MDs will be needed.

My guess is Karolinska University Hospital could be the CRO.

Other trials planned at Karolinska e.g. Herantis Pharma Plans Clinical Trial in Sweden of Its Parkinson’s Therapy CDNF

[LakeshoreLeo1953]

Thanks for the attempt at unvarnished reporting.
Difficult at best.
While mine would be different, envious of the face time
to pursue questions.

Most obvious rebuttal would be financial. How $28M 4/2018
when that was figure 12/2017. As yet unreported LPC activity
just before descent below $3?

The remainder of impression is best consolidated in three consecutive of your paragraphs:

-Alz IND still on track to be submitted this year.

-They will NOT wait for the Rett read-out before starting the Alzheimer’s trial. There’s no need to. They are completely different indications and the info learned will not really effect the Alzheimer’s study. They are completely independent.

-He was not sure as to the main reasons why our Sigma 1 agonist is superior to the others out there. He said the muscarinic may have something to do with it. He also said there is a difference between Sigma 1 activity and Sigma 1 activation. We have activation and the others have activity.

Submission by 12/31/2018 is better wiggle room than "start 3 in 2017"

Given the above assertion, does that mean RETT won't be complete by 12/31/2018? That could be inferred, but certainly would disappoint.

The Science remains the reason for hope. That is a slower process than
many investors (self included) choose to survive in an active portfolio.

AGAIN, thanks for the efforts. Many may disagree on interpretation, but NONE should discount your involvement.

BTW.....Did either you or Flakes (or other retail investors) get your questions fielded in the larger context or were those limited to the analysts?

[frrol]

Terrific notes JJ, thanks.